pharmaphorum

NOVEMBER 2, 2020

The UK drugs regulator has awarded a £1.5 million tender to a software company for an artificial intelligence tool that will be used to process “the expected high volume of COVID-19 vaccine adverse drug reactions (ADRs).”. The tender awarded to Maidenhead, Berkshire-based GenPact UK aims to “ensure that no details from the ADRs…are missed” as the UK prepares to start rolling out COVID-19 vaccines – assuming their safety and efficacy is supported in late-stage trials.

Vaccines 145

Vaccines 145

Outsourcing Pharma

NOVEMBER 4, 2020

The agency has chosen Continuity Pharma to aid in development and advancement of continuous manufacturing technology, with the help of a $1.5m grant.

104

104

Druggist

NOVEMBER 1, 2020

Lidocaine patch (brand name: Versatis medicated plaster) is a prescription-only medication, which has limited licensed use in the UK. Lidocaine patch offers a different approach to pain management as compared to standard analgesic drugs. In this post, I will review the use of lidocaine patch for back pain. The main points covered: What is lidocaine patch?

59

59

Pharma Mirror

NOVEMBER 4, 2020

To date, breast cancer is one of the most dangerous diseases. Unfortunately, it is not always possible to diagnose it early due to the lack of modern equipment in many countries. Medical tourism is getting popular, and you can easily get stage 4 breast cancer treatment in Germany. Modern hospitals in Germany have the most. The post Stage 4 Breast Cancer Treatment in Germany appeared first on Pharma Mirror Magazine.

Hospitals 52

Hospitals 52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

NOVEMBER 2, 2020

The pharmaceutical industry has sometimes been a laggard in terms of digital maturity, but the COVID-19 crisis has provided companies the impetus to rapidly implement the most cutting-edge technologies. At the heart of most of these digital advancements is AI and machine learning. With a collective sense of uncertainty, many are pinning their hopes on a vaccine and treatment, and sophisticated technology could help speed up the process of finding an effective medicine.

Vaccines 132

Vaccines Pharmaceutical Companies Pharmaceutical Companies Patient Care 132

Outsourcing Pharma

NOVEMBER 4, 2020

According to representatives from the pharma solutions provider, incorporation of CM processes, after a slow period, is expanding across the industry.

98

98

Pharma Mirror

NOVEMBER 1, 2020

Accidents happen, people get sick, unexpected health issues pop up, problems occur when you least expect it – this is why there are emergency rooms and why millions of people go to them every year. Yet, visiting the emergency room can be very stressful and scary. You don’t know what is going to happen to. The post How Hospital Emergency Rooms are Improving Care appeared first on Pharma Mirror Magazine.

Hospitals 52

Hospitals 52

pharmaphorum

NOVEMBER 3, 2020

Ring Chromosome 20 Syndrome, or (R)20, is an ultra-rare form of epilepsy with a devastating impact – yet despite huge leaps forward in gene sequencing in recent years, diagnoses are going down instead of up. We spoke to Allison Watson, co-founder of Ring 20 Research and Support, about raising awareness, building the evidence base, and the importance of helping people through a pandemic despite limited funding.

Hospitals 101

Hospitals 101

Outsourcing Pharma

NOVEMBER 2, 2020

The latest analytical report from Life Science Strategy Group reveals position and perception of the leading players and performers in the eClinical arena.

67

67

Med Ed 101

NOVEMBER 4, 2020

Hydralazine is a medication that causes vasodilation on the arterioles which ultimately leads to a reduction in blood pressure. It isn’t a medication that is used terribly often and I will discuss the reasons for this as well as other hydralazine clinical pearls you should be aware of. Hydralazine Clinical Pearls – Why Isn’t It […]. The post Hydralazine Clinical Pearls appeared first on Med Ed 101.

40

40

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Times

NOVEMBER 2, 2020

It is hoped that findings from the NIHR-funded trial will help better inform treatment decisions

56

56

pharmaphorum

NOVEMBER 4, 2020

Professor Jean-Pierre Boissel outlines the urgent need for disruptive R&D approaches that can tackle the search for COVID-19 treatments more effectively. It may not be appropriate to use the word ‘failure’ when summarising the utility of clinical trials in the search for a curative or preventative treatment for disease. For the purposes of this text, let us assume that ‘success’ and ‘failure’ will be used in reference to the objective of clinical trial designers: to obtain sufficient evidenc

Vaccines 105

Vaccines Immunization FDA 105

Outsourcing Pharma

NOVEMBER 3, 2020

The Serialized Product Intelligence application uses serialization data to help operations streamline supply-chain operations, resolve issues and more.

53

53

Med Ed 101

NOVEMBER 1, 2020

In this case scenario, we discuss the potential risk of leaving the nicotine patch on overnight. A 55-year-old female has a history of hypertension, GERD, and is currently a cigarette smoker. She has tried over 10 times in the last 15-20 years to quit smoking to no avail. She has tried varenicline, nicotine gum, and […]. The post Leaving The Nicotine Patch On Overnight appeared first on Med Ed 101.

40

40

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharma Times

NOVEMBER 2, 2020

Zejula is the first PARP inhibitor to be approved as monotherapy in the EU for patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status

40

40

pharmaphorum

NOVEMBER 5, 2020

After three brushes with cancer, Robert Weker understands the patient journey more than many – and he is determined to put that experience to good use. The avid blogger and passionate advocate retired from his R&D role four years ago to focus on his own health, and now works full time on making sure the patient voice is “in the room” when pharma companies make decisions.

Chemotherapy 95

Chemotherapy Insurance Hospitals 95

Outsourcing Pharma

NOVEMBER 5, 2020

With the Open Wearables initiative, Shimmer Research is looking to bring research professionals together on solutions for the common good of the industry.

52

52

Pharma Marketing Network

NOVEMBER 4, 2020

RJ (PMN): Hi this is RJ Lewis here for another episode of Pharma Marketing Networks Podcast. I have with me today Tom Ollerton from Automated Creative which is doing some really fascinating things when it comes to applying artificial intelligence to the creative development process in measuring process. Welcome Tom. Tom (AC): Thanks so much for having me RJ this is really brilliant to be invited on a podcast looking forward for a chat.

Compounding 52

Compounding 52

Pharma Times

NOVEMBER 2, 2020

The move gives the French drug giant access to Kiadis' natural killer cell technology platform

49

49

pharmaphorum

NOVEMBER 5, 2020

An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Co’s Keytruda – both leading their respective drug classes in the treatment of non-small cell lung cancer (NSCLC). The two phase 1/2 trials are zeroing in on NSCLC patients with specific molecular biomarkers, to see if adding Genprex’ Reqorsa (quaratusugene ozeplasmid) – which delivers a gene that suppresses tumour growth – can enhance the activity of the AZ and Merck

FDA 98

FDA 98

Outsourcing Pharma

NOVEMBER 3, 2020

A leader from life-science solutions firm RBW Consulting says remote monitoring can help clinical trials move forward, despite formidable challenges.

52

52

Druggist

NOVEMBER 6, 2020

Chesty cough, also known as a productive cough, is characterised by overproduction of mucus. Chesty cough can commonly be a symptom of a common cold, but also other acute conditions such as bronchitis, or long term disease, for example, Chronic Obstructive Pulmonary Disease (COPD). Mucus accompanying a chesty cough can be clear or coloured (for example, yellow).

Immunization 69

Immunization 69

Pharma Times

NOVEMBER 3, 2020

Obesity management treatment recommended following confidential discount

55

55

pharmaphorum

NOVEMBER 2, 2020

It’s a safe bet that most people’s first introduction to CDISC standards is through the Study Data Tabulation Model (SDTM). This is a content standard that ensures clinical data is submitted in a consistent manner, helping to reduce review time and facilitating cross-study analysis. Another content standard, the Analysis Data Model (ADaM), aims to perform a similar function for analysis datasets.

FDA 89

FDA 89

Outsourcing Pharma

NOVEMBER 2, 2020

With an infusion of capital from investors 1315 Capital, ProSciento is setting its sights on expansion of its specialized clinical research services.

52

52

pharmaphorum

NOVEMBER 2, 2020

Sanofi is to acquire Kiadis, a biotech specialising in therapies based around ‘off the shelf’ natural killer (NK) cells, for 308 million euros ($353 million). The French pharma is buying Kiadis for 5.45 euros per share in cash, an offer price representing a premium of 272% over the biotech’s closing price on Friday evening on Amsterdam’s Euronext market.

81

81

pharmaphorum

NOVEMBER 3, 2020

It could be possible to detect whether someone has COVID-19 or not, just from the sound of their coughing. That’s the conclusion of testing of an artificial intelligence (AI) algorithm developed by the Massachusetts Institute of Technology (MIT), which was able to detect around 98% of cases of COVID-19 from a forced cough delivered down a cell phone – confirmed by coronavirus testing.

Hospitals 84

Hospitals 84

pharmaphorum

NOVEMBER 4, 2020

Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine – in a head-to-head trial. The HER-MES trial found that Aimovig (erenumab) was more effective at preventing migraine attacks and also better tolerated than topiramate, a generic epilepsy drug which is known to have side effects like sleepiness, dizziness, diarrhoea and nausea.

73

73

pharmaphorum

NOVEMBER 4, 2020

Ireland-based Fountain Healthcare Partners has raised another €125 million ($131 million) for its third life sciences fund – 25% ahead of its target – and says it will pump most of the money into European therapeutics and medical device companies. The latest cash injection adds to the €118 million initially raised by Fountain Healthcare for the fund in May 2019, and brings the total value managed by the company above the €300 million mark.

FDA 73

FDA 73

pharmaphorum

NOVEMBER 6, 2020

Merck & Co has agreed to buy California biotech VelosBio and its experimental cancer drug for $2.75 billion in cash. Known as MSD outside North America, the big pharma already has a firm foothold in cancer thanks to its immunotherapy Keytruda (pembrolizumab), which has been on the market for several years and has proven to be effective across a wide range of oncology indications.

Labelling 75

Labelling 75

pharmaphorum

NOVEMBER 6, 2020

Ahead of Frontiers Health 2020, steering committee members Roberto Ascione and Paul Tunnah from Healthware give us their thoughts on the trends driving the bright future of digital health. It might be easy to think of pharma and healthcare as conservative industries, but the reality is that digital health is now far further along than we predicted it would have been 10 years ago – or even one year ago.

72

72

pharmaphorum

NOVEMBER 4, 2020

The European Commission has approved Roche’s Tecentriq immunotherapy, in combination with its established cancer drug Avastin, for patients with the most common form of liver cancer. Tecentriq (atezolizumab) can be used with Avastin (bevacizumab) for adults with advanced or unresectable hepatocellular carcinoma (HCC) who have not received systemic therapy.

Adverse Reactions 64

Adverse Reactions Immunization FDA 64

pharmaphorum

NOVEMBER 2, 2020

COVID-19 vaccines could be approved and available early next year in the UK ahead of European countries, after its national regulator began its own rolling reviews of shots from AstraZeneca and Moderna. AstraZeneca has confirmed that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has begun a fast-track rolling review of its AZD1222, the COVID-19 vaccine it developed in conjunction with Oxford University.

Vaccines 64

Vaccines 64

pharmaphorum

NOVEMBER 5, 2020

Talking Medicines has raised £1.1 million ($1.4 million) in funding that will be used to develop an artificial intelligence (AI) data platform that can be used by pharma companies to gain insights into how patients perceive them. The Glasgow-based company – which is behind the MedSmart app that helps patients keep a digital records of their medicines and symptoms using barcodes – says it will use the cash injection to launch a new AI data platform which will “translate what patients are saying i

59

59